Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in C
Why Wall Street Is Backing These 3 Comeback Stocks
06:44pm, Tuesday, 28'th Oct 2025
A company's comeback story can mean a significant opportunity for investors to win returns in the financial world. Of course, when a stock has shed a sizable portion of its value in recent memory, man
Insiders Are Buying These 3 Stocks Hand Over Fist
02:21pm, Tuesday, 28'th Oct 2025
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
1 Monster Stock in the Making to Buy and Hold
05:51am, Monday, 27'th Oct 2025
Summit Therapeutics' ivonescimab continues to ace phase 3 studies against approved drugs. The investigational cancer medicine could eventually become one of the world's best-selling therapies.
Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech
08:45am, Saturday, 25'th Oct 2025
While insider buying is typically slower when markets are near all-time highs and when earnings-reporting season is in full swing, it never seems to dry up altogether.
Summit Therapeutics: A Risky Bet in the Biotech Arena?
07:00pm, Friday, 24'th Oct 2025
Explore the exciting world of Summit Therapeutics (SMMT +2.83%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into m
Summit Therapeutics Raises $500 Million in Private Placement
08:00am, Wednesday, 22'nd Oct 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biot
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
02:46pm, Tuesday, 21'st Oct 2025
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript
05:05pm, Monday, 20'th Oct 2025
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
02:35pm, Monday, 20'th Oct 2025
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increa
What's Going On With Summit Therapeutics Stock On Monday?
10:05am, Monday, 20'th Oct 2025
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsore
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advis
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, p
